SYMB-104

N/A

Report date: 2025/01/26 15:50:51

NME

Base Information

Drug NameSYMB-104

Drug Alias Namepolysaccharide A (Symbiotix)specific bacterial capsular polysaccharide (Symbiotix Biotherapies)specific bacterial capsular polysaccharide (Symbiotix Biotherapies)Reglemer-based therapy (Symbiotix Biotherapies)SYMB-104

ClassificationSmall molecules > LipidSmall molecules > Carbohydrate > Oligosaccharide

Mechanisms of ActionT-cell receptor agonists

TargetsT-cell receptor

Therapy Area/IndicationsMultiple SclerosisInflammatory Bowel Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSymbiotix Biotherapies Inc

China Registration ClassN/A

Develop Information

Active CompaniesSymbiotix Biotherapies Inc

Inactive CompaniesN/A

Active IndicationsMultiple SclerosisInflammatory Bowel Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A